Project Grant K01NS142018
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research to investigate non-apoptotic forms of cell death in glioblastoma (GBM), the most deadly primary brain tumor in adults. The $595,047 award to the University of California, Los Angeles (UCLA) aims to: 1) define the relationship between molecular and metabolic features...
- This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to uncover the effects of standard-of-care therapy on immune and neoplastic cell population dynamics in pre-clinical mouse models of glioblastoma (GBM) and analysis of human GBM samples. The goal is to identify tumor microenvironment areas of therapeutic...
- This $3,155,815 Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, supports research to develop advanced magnetic resonance imaging techniques for non-invasive measurement of glutamate metabolism in glioblastoma brain tumors. The primary awardee is Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, which will leverage its expertise in medical research, imaging technologies, and...
- This federal Project Grant award of $131,360 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research at the University of New Haven to characterize the long non-coding RNA GIHCG and assess its potential as a therapeutic target for glioblastoma, the most aggressive form of brain cancer. The 4-year project aims to use CRISPR/Cas9 gene editing to...
- This $245,434 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at the University of Pennsylvania to map the neural circuit connectivity of human high-grade glioma brain tumors in a mouse model. The goal is to define the whole-brain inputs onto glioblastoma cells using monosynaptic tracing techniques to understand how neuronal...
- This federal Project Grant award for $659,325.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to understand the role of mutant IDH1 in glioma pathophysiology and immune response mechanisms. The research will use a novel murine glioma model developed by incorporating genetic lesions into neural progenitor cells using the...
- This Project Grant award of $652,751 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to engineer antibody drug conjugates (ADCs) designed to enhance the therapeutic window for treating glioblastoma (GBM) and other central nervous system cancers. The research, conducted by the Mayo Clinic, aims to leverage key findings from prior preclinical studies...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, will fund research to target cell-scaffolding proteins that contribute to radioresistance in glioblastoma, an aggressive brain cancer. The $448,250 award to The Research Foundation For The State University Of New York, operating as Upstate Medical Center, will support a 2-year...
- This federal Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to explore the mechanism of Notch inhibition resistance in glioblastoma (GBM) cancer stem-like cells. The goal is to develop novel therapies for this deadly brain cancer. The research project, led by the Regents of the University of Michigan, will identify GBM...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $229,078 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of North Carolina at Chapel Hill to investigate "Ferroptosis Sensitization in Glioblastoma". The project aims to leverage positron emission tomography (PET) imaging with the FSPG tracer to study the effects of dietary cysteine/methionine deprivation and radiation therapy on inducing ferroptosis, a form of regulated cell death, in glioblastoma brain tumor models. The 5-year project, running from August 2025 to July 2030, will seek to develop this PET imaging biomarker approach as a way to monitor and enhance ferroptosis-based treatment strategies for this highly aggressive type of brain cancer.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $229.1k | 8/6/25 |